touchNEUROLOGY Highlights from AAN 2019 – Day 1

Tolebrutinib is an oral, CNS-penetrant Bruton’s tyrosine kinase inhibitor with dual mechanism of action: peripheral B cell modulation and re-establishment of CNS microglial homeostasis. Dr Jiwon Oh (St. Michael’s Hospital, University of Toronto, Canada) joins us to discuss the phase 2b trial (NCT03889639), investigating safety and efficacy of tolebrutinib in patients with relapsing multiple sclerosis. […]

Prof. Bruce Cree (UCSF Multiple Sclerosis Centre, San Francisco, CA, USA) discusses the potential use of bruton tyrosine kinase inhibitors (BTKis) in the treatment of multiple sclerosis. Prof. Cree discusses BTKis novel mechanism of action and the rationale behind the investigation of this new class of drugs. Question: What are the key clinical highlights in […]

Ublituximab is a novel glycoengineered monoclonal antibody treatment under investigation for relapsing remitting multiple sclerosis. Prof Bruce Cree (UCSF Multiple Sclerosis Centre, San Francisco, CA, USA) discusses the phase 3 ULTIMATE I and II studies, and the positive results from the tertiary analysis of the data that investigated disability improvements in patients with relapsing multiple […]